Major keywords: Dermatofibroma, Dermatofibrosarcoma protuberans, Immunohistochemistry, Diagnostic markers

Title: Immunohistochemical profiles of dermatofibroma and dermatofibrosarcoma protuberans: A scoping review

Authors: Céline S. C. Hardy^{1,2#}, Ali Razavi¹, Natalie Nunez¹, William Fitzmaurice¹, Loma Dave¹, Amy R. Slutzky³, Kaitlin Vanderbeck⁴, Ramsay Farah⁵.

Affiliations: ¹ College of Medicine, Upstate Medical University, Syracuse, New York.

² Department of Microbiology and Immunology, Upstate Medical University, Syracuse, New York, USA. ³ Health Sciences Library, Upstate Medical University, Syracuse, New York.

⁴ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario.

⁵ Division of Dermatology, Upstate Medical University, Syracuse, New York

#Adress correspondence to hardyce@upstate.edu

Conflicts of interest: the authors have no conflicts to declare.

Acknowledgements: the authors have no acknowledgements to report.

Author contributions: Céline S. C. Hardy, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review and editing | Ali S. Razavi, Conceptualization, Data curation, Investigation, Methodology, Writing – review and editing | Natalie Nunez, Data curation, Investigation, Writing – review and editing | William Fitzmaurice, Data curation, Investigation, Writing – review and editing | Loma Dave, Data curation, Investigation, Writing – review and editing | Amy R. Slutzky, Data curation, Methodology, Supervision, Writing – review and editing | Kaitlin Vanderbeck, Conceptualization, Data curation, Investigation, Methodology, Supervision, Writing – review and editing | Ramsay Farah, Conceptualization, Investigation, Methodology, Supervision, Writing – review and editing | review and editing

Immunohistochemical profiles of dermatofibroma and dermatofibrosarcoma protuberans:

2 A scoping review

1

3

6

7

18

19

- 4 Keywords: Dermatofibroma, Dermatofibrosarcoma protuberans, Immunohistochemistry,
- 5 Diagnostic markers

ABSTRACT

- 8 This review summarizes the immunohistochemical profiles of dermatofibroma (DF) and
- 9 dermatofibrosarcoma protuberans (DFSP) as reported by primary literature in the past 10 years.
- 10 63 studies were included in the review, with staining information for a total of 99 unique IHC
- markers reported. The most commonly reported stains were CD34, SMA, S100, and FXIIIa.
- Most studies applied IHC either to explore descriptive features of DF or DFSP or to determine
- their utility in diagnostic identification of the lesions. A number of studies applied novel
- biomarkers which may hold promise for distinguishing DF and DFSP, namely WT1, Cx43, LSP-
- 15 1, and PHH3, which demonstrated considerable expression differences between the two lesions.
- 16 This review highlights the need for validation of existing and emerging IHC markers for the
- 17 diagnosis of DF and DFSP.

1.INTRODUCTION

- 20 Dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP) are spindle cell lesions with
- 21 overlapping clinical and histologic features. DF, also known as benign fibrous histiocytoma
- 22 (BFH), are benign soft tissue tumors with good prognosis. Contrastingly, DFSP are locally
- 23 aggressive tumors which frequently recur. Additionally, DFSPs may undergo fibrosarcomatous
- transformation, which portends a higher rate recurrence and increased risk of metastasis^{1,2}.
- 25 Appropriate identification of DFs and DFSPs from each other and their histologic mimics is of
- 26 critical importance to ensure proper clinical management. Despite their clinical divergence, these
- 27 two lesions share many histologic and morphologic features. Morphologically, both are spindled
- 28 lesions which may show increased cellularity and mixed fascicular, whorled or storiform growth
- 29 patterns. Given their clinical and histologic similarities, it may be challenging to differentiate
- 30 these two entities on histologic grounds alone, particularly in limited biopsies. Therefore,
- 31 immunohistochemistry (IHC) is often used to differentiate DF from DFSP and is a mainstay in

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 58

59

60

61 62 their diagnosis. Key immunohistochemical markers classically include cluster of differentiation 34 (CD34) and Factor XIIIa (FXIIIa), where CD34 is known to be strongly positive in over 90% of DFSP^{3,4}, while DFs are known to be negative for CD34 but positive for factor XIIIa ^{5,6}. Additional markers used to distinguish between these lesions from each other and their mimics include smooth muscle actin (SMA), S-100, and Desmin. Within both DF and DFSP, IHC can also inform or validate the presence of histologic subtypes, pathogenic/driving gene fusions, and specific pathogenic mechanisms within these lesions. However, despite the elaborate use of IHC in classifying and studying DF and DFSP, the diagnostic specificity of the currently employed markers is imperfect. Although a number of novel markers have been suggested, constantly emerging literature coupled with a lack of validated data can lead to confusion about which markers are the most effective. For this reason, we conducted a scoping review of the literature in order to systematically report IHC staining data on these lesions, summarize the utility of existing markers, and highlight emerging markers specifically useful for distinguishing DF and DFSP. An effective summary of the current literature on the IHC staining profiles of these lesions is useful for consolidating information and providing insight into prospective biomarkers which require additional validation. 2.METHODS 2.1 Study design This review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines⁷. An a priori study protocol was registered in the Open Science Framework (https://doi.org/10.17605/OSF.IO/92EWY). 2.2 Information sources and search strategy Four databases – PubMed, Embase (Elsevier), Scopus (Elsevier), and the Cochrane Library – were searched for relevant articles. For each database, key concepts were defined using combinations of controlled vocabulary (where available) and keywords, to maximize search sensitivity. The PubMed search strategy is given below; full search strategies are given in Appendix X.

63 PubMed search strategy: ("Histiocytoma, Benign Fibrous" [Mesh] OR "Dermatofibrosarcoma" [Mesh] 64 65 OR "histiocytoma*" [tiab] OR dermatofibro* [tiab] OR DFSP [tiab] OR "nodular subepidermal fibrosis"[tiab]) 66 **AND** 67 ("Immunohistochemistry" [Mesh] OR immunohistochem* [tiab] OR IHC [tiab] OR 68 immunostain*[tiab]) 69 Database search strategies limited search results to publication dates over the past 20 years 70 71 (2003-present). Final searches for all databases were run on June 24, 2024. 72 73 2.3 Eligibility criteria 74 Studies were selected for inclusion in the review if they: evaluated protein expression by immunohistochemistry (IHC), specifically 75 76 immunoperoxidase staining, of tissue specimens from human subjects of histologically 77 confirmed cases of cutaneous DF (including benign fibrous histiocytoma, cutaneous 78 fibrous histiocytoma, and epithelioid fibrous histiocytoma) or DFSP; reported the number of lesions evaluated and the fraction of lesions positive or negative 79 80 for a given marker for greater than 5 lesions; focused on evaluating the tumor cell compartment (as opposed to stromal or immune cell 81 82 profiling); and 83 • were published in English, French, or Spanish. 84 The following types of studies were excluded from the review: review articles, case reports, 85 conference abstracts, in vitro studies, and animal studies. 86 87 2.4 Article screening 88 Results from all database searches were uploaded to Covidence (Veritas Health Innovation, 89 Melbourne, Australia). Duplicate records were identified and removed automatically by 90 Covidence, with all duplicate pairs manually confirmed (AS). Then two reviewers (AR, WF, NN, and/or LD) independently screened each title/abstract for inclusion in the review, with any 91 92 conflicts resolved via discussion with content experts (RF and/or KV). After title/abstract 93 screening was complete, a decision was made to limit the review to studies published over the

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

past 10 years (2013-present), and to exclude case studies and case series evaluating fewer than five lesions. These decisions were made both due to practical/time constraints and in consideration of the relevance of IHC markers evaluated, pertinence and consistency of antibody clones and staining protocols used. Full-text articles were then screened independently by two reviewers (AR, WF, NN, and/or CH), with any conflicts resolved as described above. 2.5 Data abstraction Data collection was performed first by one of two independent reviewers (CH, AR) and then independently verified by the second reviewer. The following data were collected and charted using Microsoft Excel: Study characteristics (article title, publication date, study aim, study geographic location) Lesion information (type and number of lesions studied, sample/specimen type, histologic information if available) IHC characteristics (IHC stains performed, method of IHC evaluation, specific antibodies used, staining expression results for lesions of interest) 3.RESULTS 3.1 Selection and characteristics of sources of evidence Database searches identified 2506 distinct articles. Following title/abstract and full text screening, 63 articles were selected for inclusion in the review^{8–70} (**Fig. 1**). Of those 63 studies, 15 contained IHC data for DF only, 28 for DFSP only, and 20 studies contained data for both DF and DFSP. Complete characteristics of data extracted from all articles -- including geographic location, date of sample collection, and study aim -- are summarized in supplemental **Table S1**. 3.2 Immunohistochemical markers applied in DF and DFSP Across all studies, a total of 99 IHC markers were evaluated, of which the most discussed markers included CD34, SMA, S100, FXIIIa, Desmin, and Ki-67 (Fig. 2). Cluster of differentiation 68 (CD68), anaplastic lymphoma kinase (ALK), epithelial membrane antigen (EMA), and pan-cytokeratin (PanCK) were also frequently discussed (Fig. 2). The purpose of IHC application in these studies could be broadly categorized as descriptive, diagnostic, or prognostic. Summary tables of IHC biomarkers applied and their indication or purpose of

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

application in DF and DFSP are summarized in **Table 1** and **Table 2**, respectively. The majority of IHC markers were applied for descriptive or diagnostic purposes. Descriptive studies focused primarily on characterizing expression of a given marker in specific entities, determining associations of expression with variant histology, or evaluating the role of expression in disease pathogenesis. Of the studies evaluating IHC staining with respect to its diagnostic utility, 37 studies assessed a role for IHC in distinguishing histologic mimics from either DF or DFSP, while 15 studies contained data focused specifically on distinguishing DF and DFSP from each other. 3.3 Immunohistochemical markers for distinguishing DF and DFSP When focusing on studies aiming to characterize differences in immunohistochemical expression between DF and DFSP (n=13), a total of 30 IHC markers were evaluated. CD34 and Factor XIIIa were the most frequently employed markers for distinguishing DF and DFSP in the reviewed studies (Fig. S1). Summary statistics of the staining expression of classical markers in DF compared to DFSP across all studies are provided in **Table 3**. CD34 was frequently strongly positive in DFSPs (95.8%), while negative in DF (15.5%), and contrastingly Factor XIIIa was positive in DF (86.2%) but more frequently negative in DFSP (24.9%) (**Table 3**). SMA, ALK, CD99, and CD68 were more frequently positive in DF than DFSP, while S100 and Desmin tended to be negative in both (Table 3). Many studies also provided data regarding more novel markers evaluated for distinguishing between the two lesions, these included: Wilm's tumor 1 (WT1), ETS transcription factor (ERG), podoplanin (D2-40), phosphohistone H3 (PHH3), p75, connexin 43 (Cx43), fibroblast growth factor 2 (FGF2), fibroblast growth factor receptor 4 (FGFR4), lymphocyte specific protein 1 (LSP-1), p16, and Ki-67 (**Table 4**). Of these, studies evaluating WT1, Cx43 and LSP-1 demonstrated the greatest difference in expression between DF and DFSP. Complete expression data for all markers across all studies are available in supplemental Table S2. **4.DISCUSSION** In this study, we summarize the applications of IHC markers in DF and DFSP and their utility for distinguishing these lesions as reported in the literature over the past 10 years. In this review a total of 99 unique IHC markers were reported in the 63 studies evaluated. Interpretation of the

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

expression data of these markers and the utility of key markers for distinguishing DF and DFSP will be elaborated upon in the following sections. 4.1 Accuracy of classical markers for distinguishing DF and DFSP Classical markers for diagnosis of DF and DFSP such as CD34, FXIIIa, S-100, and Desmin all demonstrated expression in expected proportions and patterns according to the literature⁷¹. However, it is important to note that despite these overall trends there was marked intra-study variability for most markers. For example, even CD34, one of the most specific markers positive in DFSP, was weakly or focally positive in ~15% of DFs^{42,53,64}. Most commonly, conventional DFs did show negativity for CD34, however many DFs which contained variant histology were specifically noted to have focal CD34 expression. This highlights previous observations that application of CD34 alone is insufficient, and the need for additional markers to clarify the identity of lesions where CD34 expression is ambiguous or present focally. Interestingly, expression of classical markers CD99 and CD68 were reported of variable diagnostic utility to distinguish DF and DFSP. While one study showed that DFs have higher frequency of CD99 positivity compared to DFSPs³⁷ and additional data supports there being evidently low expression of CD99 in DFSPs (0% positivity)^{23,69}, data from Song et al. shows 50% positivity in both lesions^{23,37,60,69}. Altogether, there remains work to be done to determine the expression in DF compared to DFSP of classical markers using additional sample sets. Beyond these diagnostic applications, there is a need to better understand the expression of classical markers within these lesion types in regions with variant histology. 4.2 Emerging markers for distinguishing DF and DFSP Given the imperfect specificity of classical markers, there is an inherent need to identify and validate the utility of more novel markers for diagnostic dilemmas. A number of the reviewed studies assessed a role for novel markers in distinguishing DF and DFSP from each other or their mimics. Promising emerging IHC markers included WT1, LSP-1, Cx43, and a combined Ki67 and PHH3 score, which warrant further investigation ^{12,26,34,50}. Piombino et al. assessed the expression of WT1, a master transcriptional/translational regulator in cell differentiation in a series of soft tissue neoplasms of mesenchymal origin. They found that cytoplasmic WT1 expression was absent in all evaluated DFs, but positive in 94.7% of DFSPs⁵⁰. Similar to WT1,

connexin 43 (Cx43) was evaluated by Fernandez-Flores et al. because of its suspected role in pathogenesis. Specifically, with respect to propensity for invasion given that connexins are involved in mediating cell-cell adhesion. Cx43 demonstrated excellent specificity for the lesions, with 100% positivity in DF and 0% positivity in DFSP²⁶. Another promising marker studied was Leukocyte specific protein 1 (LSP-1) which was also highly positive in DF, while negative in DFSP³⁴.

Although Ki-67 is traditionally thought of as a prognostic, rather than diagnostic biomarker, Agarwal et al. identify potential utility of Ki-67 for distinguishing DF and DFSP in a combined scoring system with PHH3¹². PHH3 is expressed in M phase and is therefore useful in determining mitotic counts. The goal of this study was to assess the utility of a combined scoring system incorporating both the Ki67 index and PHH3 mitotic count, where they found that the mean Ki67 proliferation index and mitotic count were significantly higher in DF compared to DFSP¹². Interestingly, this study may highlight that the integration of multiple features or biomarkers can provide more comprehensive information than looking for one "silver bullet" IHC marker to clarify the diagnosis.

D2-40 is another emerging marker for which a number of studies suggested utility, however these data were contradictory and require additional validation. A number of studies suggest D2-40 for aiding in the differential diagnosis of DF and DFSP, where D2-40 is positive in DF and negative in DFSP^{14,53}. However, data from Song et al. demonstrated only 33% positivity in DF⁶⁰. Like D2-20, markers such as ERG, CD10, and p75 have some data to indicate utility, but require further investigation due to conflicting data, or low sample numbers. Across all markers, it should be noted that small sample size, differences in antibody clones, staining protocols, and staining evaluation methodology remain a challenge that likely contribute greatly to the observed variability across studies evaluating a given marker.

5. Conclusions

In this review, we report the IHC expression in DF and DFSP of traditional diagnostic markers as well as novel markers which may hold diagnostic utility according to the literature from the past 10 years. Of the markers discussed with diagnostic relevance, traditional markers such as CD34, SMA, and FXIIIa were the most common and demonstrated expected expression patterns in DF and DFSP. Additionally, studies investigated novel markers for distinguishing DF and

- 218 DFSP such as WT1, Cx43, LSP-1, and PHH3/Ki-67. Future studies should seek to continue
- investigating the expression of these markers and their potential utility for diagnostic application.

221 Data availability

220

224

225

- Data supporting the findings of this study are available within the article and/or its
- supplementary material.

REFERENCES

- 226 1. Abbott JJ, Oliveira AM, Nascimento AG. The Prognostic Significance of Fibrosarcomatous
- Transformation in Dermatofibrosarcoma Protuberans. Am J Surg Pathol. 2006;30(4).
- 228 https://journals.lww.com/ajsp/fulltext/2006/04000/the prognostic significance of fibrosa
- rcomatous.2.aspx
- 230 2. Reifs CMA, Salido-Vallejo R. Dermatofibrosarcoma protuberans with fibrosarcomatous
- 231 transformation. An Bras Dermatol. 2016;91(5):700-701. doi:10.1590/abd1806-
- 232 4841.20164886
- 233 3. Abenoza P, Lillemoe T. CD34 and Factor XIII a in the Differential Diagnosis of
- 234 Dermatofibroma and Dermatofibrosarcoma Protuberans: *Am J Dermatopathol*.
- 235 1993;15(5):429-434. doi:10.1097/00000372-199310000-00003
- 236 4. Llombart B, Sanmartín O, López-Guerrero JA, et al. Dermatofibrosarcoma protuberans:
- clinical, pathological, and genetic (COL1A1-PDGFB) study with therapeutic implications.
- 238 *Histopathology*. 2009;54(7):860-872. doi:10.1111/j.1365-2559.2009.03310.x
- 5. CERIO R, SPAULL J, JONES EW. Histiocytoma cutis: a tumour of dermal dendrocytes (dermal
- 240 dendrocytoma). Br J Dermatol. 1989;120(2):197-206. doi:10.1111/j.1365-
- 241 2133.1989.tb07783.x
- 242 6. RAMANI P, BRADLEY NJ, FLETCHER CDM. QBEND/10, a new monoclonal antibody to
- endothelium: assessment of its diagnostic utility in paraffin sections. *Histopathology*.
- 244 1990;17(3):237-242. doi:10.1111/j.1365-2559.1990.tb00713.x
- 7. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR):
- 246 Checklist and Explanation. *Ann Intern Med.* 2018;169(7):467-473. doi:10.7326/M18-0850
- 247 8. Abdaljaleel MYO, North JP. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant
- 248 Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A
- Potential Diagnostic Pitfall. Am J Dermatopathol. 2017;39(2):83-88.
- 250 doi:10.1097/DAD.0000000000000584

251 9. Abdaljaleel M, North JP. Positive MITF and NKI/C3 Expression in Cellular Neurothekeoma

and Dermatofibroma. *Appl Immunohistochem Mol Morphol*. 2021;29(6):440-445.

- 253 doi:10.1097/PAI.0000000000000889
- 254 10. Adem D, Yazici S, Ozsen M, et al. The Ki-67 proliferation index predicts recurrence-free
- 255 survival in patients with dermatofibrosarcoma protuberans. Bosn J Basic Med Sci. Published
- 256 online October 20, 2020. doi:10.17305/bjbms.2020.5088
- 257 11. Afifi MM, Elnouaem MI, Omar EM, El-Komary I. Oral and Extraoral Intermediate Tumors:
- 258 Are MMP-9 and Ki-67 Biomarkers Correlated to Their High Recurrence Rates? *Appl*
- 259 *Immunohistochem Mol Morphol.* 2020;28(3):229-236. doi:10.1097/PAI.0000000000000703
- 260 12. Agarwal A, Gopinath A, Tetzlaff MT, Prieto VG. Phosphohistone-H3 and Ki67: Useful
- 261 Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and
- Atypical Fibrohistiocytic Lesions. *Am J Dermatopathol*. 2017;39(7):504-507.
- 263 doi:10.1097/DAD.0000000000000690
- 13. AlOtaibi MN, Basfar AS, Jawhari AM, et al. The Burden of Skin Cancers in Saudi Arabia
- Through 2011-2022. Cureus. Published online September 11, 2023.
- 266 doi:10.7759/cureus.45052
- 14. Aslam M, Khan FW, Chughtai AS, Naeem A, Bashir A, Khan A. Frequency of Expression of
- D240 in Dermatofibroma A diagnostic study. *Pak J Med Health Sci.* 2022;16(1):37-39.
- 269 doi:10.53350/pjmhs2216137
- 270 15. Berklite L, Ranganathan S, John I, Picarsic J, Santoro L, Alaggio R. Fibrous
- 271 histiocytoma/dermatofibroma in children: the same as adults? *Hum Pathol*. 2020;99:107-
- 272 115. doi:10.1016/j.humpath.2020.03.012
- 16. Berklite L, John I, Ranganathan S, Parafioriti A, Alaggio R. SOX9 Immunohistochemistry in
- 274 the Distinction of Angiomatoid Fibrous Histiocytoma From Histologic Mimics: Diagnostic
- Utility and Pitfalls. Appl Immunohistochem Mol Morphol. 2020;28(8):635-640.
- 276 doi:10.1097/PAI.0000000000000809
- 17. Brčić I, Godschachner TM, Bergovec M, et al. Broadening the spectrum of NTRK rearranged
- 278 mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification
- 279 of NTRK fusions. *Mod Pathol*. 2021;34(2):396-407. doi:10.1038/s41379-020-00657-x
- 280 18. Cammareri C, Beltzung F, Michal M, et al. PRAME immunohistochemistry in soft tissue
- tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially
- useful diagnostic applications. *Virchows Arch.* 2023;483(2):145-156. doi:10.1007/s00428-
- 283 023-03606-6
- 19. Campione E, Di Prete M, Costanza G, et al. Increased Occurrence of Cutaneous Leiomyomas
- and Dermatofibromas in Patients with Uterine Leiomyomas without Fumarate Hydratase

286 Gene Mutations. *Dermatopathology*. 2023;10(3):231-243. 287 doi:10.3390/dermatopathology10030032

- 20. Cheah AL, Billings SD, Goldblum JR, Carver P, Tanas MZ, Rubin BP. STAT6 rabbit monoclonal
- antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics. *Pathology (Phila*). 2014;46(5):389-395. doi:10.1097/PAT.000000000000122
- 291 21. Cleven AHG, Sannaa GAA, Briaire-de Bruijn I, et al. Loss of H3K27 tri-methylation is a
- 292 diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an
- inferior survival. *Mod Pathol.* 2016;29(6):582-590. doi:10.1038/modpathol.2016.45
- 29. Dahiya S, Tomar R, Ahuja M, et al. Dermatofibrosarcoma protuberans: Clinicopathological
- 295 spectrum with emphasis on lymph node metastasis and fibrosarcomatous transformation. J
- 296 Cancer Res Ther. 2022;18(9):439. doi:10.4103/jcrt.JCRT_370_20
- 297 23. Dai Z, He Y, Zhang X, et al. Head-and-neck dermatofibrosarcoma protuberans: Survival
- analysis and Clinically relevant immunohistochemical indicators. *Oral Dis.* 2024;30(3):1040-
- 299 1051. doi:10.1111/odi.14495
- 300 24. Doyle LA, Mariño-Enriquez A, Fletcher CD, Hornick JL. ALK rearrangement and
- 301 overexpression in epithelioid fibrous histiocytoma. *Mod Pathol.* 2015;28(7):904-912.
- 302 doi:10.1038/modpathol.2015.49
- 303 25. Effiom OA, Olurotimi Olojede AC, Akinde OR, Olawuyi AB, Amoo AT, Arotiba GT.
- 304 Dermatofibrosarcoma protuberans: clinicopathologic presentation in Nigerians. Pan Afr
- 305 *Med J.* 2018;31. doi:10.11604/pamj.2018.31.25.13665
- 306 26. Fernandez-Flores A, Varela-Vazquez A, Mayan MD, Fonseca E. Connexin 43 in
- 307 Dermatofibroma and Dermatofibrosarcoma Protuberans: Diagnostic, Pathogenic, and
- Therapeutic Implications. *Am J Dermatopathol*. 2023;45(12):812-815.
- 309 doi:10.1097/DAD.0000000000002562
- 310 27. Ha SY, Lee SE, Kwon MJ, et al. PDGFB rearrangement in dermatofibrosarcoma protuberans:
- 311 correlation with clinicopathologic characteristics and clinical implications. *Hum Pathol*.
- 312 2013;44(7):1300-1309. doi:10.1016/j.humpath.2012.09.021
- 313 28. Han Q, Chen M, Yang J, Du T, Peng H. Dermatofibrosarcoma protuberans of the face: A
- 314 clinicopathologic and molecular study of 34 cases. JDDG J Dtsch Dermatol Ges.
- 315 2022;20(11):1463-1473. doi:10.1111/ddg.14882
- 316 29. Hengy M, Veenstra J, Perry K, Ozog DM, Friedman BJ. ETS-related Gene (ERG) is
- 317 Differentially Expressed in Dermatofibroma (Fibrous Histiocytoma) as Compared With
- 318 Dermatofibrosarcoma Protuberans and Hypertrophic Scars: A Pilot Immunohistochemical
- 319 Study. Appl Immunohistochem Mol Morphol. 2022;30(6):453-458.
- 320 doi:10.1097/PAI.0000000000001030

30. Hiraki-Hotokebuchi Y, Yamada Y, Kohashi K, et al. Alteration of PDGFRβ-Akt-mTOR pathway

322 signaling in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. *Hum*

- 323 *Pathol.* 2017;67:60-68. doi:10.1016/j.humpath.2017.07.001
- 31. Hung YP, Fletcher CDM, Hornick JL. FOSB is a Useful Diagnostic Marker for Pseudomyogenic
- 325 Hemangioendothelioma. *Am J Surg Pathol.* 2017;41(5):596-606.
- 326 doi:10.1097/PAS.0000000000000795
- 327 32. Ishigami T, Hida Y, Matsudate Y, Murao K, Kubo Y. The involvement of fibroblast growth
- 328 factor receptor signaling pathways in dermatofibroma and dermatofibrosarcoma
- 329 protuberans. J Med Invest. 2013;60(1.2):106-113. doi:10.2152/jmi.60.106
- 33. Jahanseir K, Xing D, Greipp PT, et al. PDGFB Rearrangements in Dermatofibrosarcoma
- Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous
- 332 Variants. *Int J Gynecol Pathol*. 2018;37(6):537-546. doi:10.1097/PGP.0000000000000472
- 333 34. Jin SY, Choi JS, Choi YL, Choi YL, Kim DH, Lee SH. Identification of Leukocyte-Specific Protein
- 1-Positive Cells: A Clue to the Cell of Origin and a Marker for the Diagnosis of
- 335 Dermatofibroma. Ann Dermatol. 2015;27(2):157. doi:10.5021/ad.2015.27.2.157
- 35. Karanian M, Pérot G, Coindre JM, Chibon F, Pedeutour F, Neuville A. Fluorescence in situ
- 337 hybridization analysis is a helpful test for the diagnosis of dermatofibrosarcoma
- 338 protuberans. *Mod Pathol*. 2015;28(2):230-237. doi:10.1038/modpathol.2014.97
- 36. Kazakov DV, Kyrpychova L, Martinek P, et al. ALK Gene Fusions in Epithelioid Fibrous
- 340 Histiocytoma: A Study of 14 Cases, With New Histopathological Findings. Am J
- 341 *Dermatopathol.* 2018;40(11):805-814. doi:10.1097/DAD.000000000001085
- 37. Kazlouskaya V, Malhotra S, Kabigting FD, Lal K, Elston DM. CD99 Expression in
- 343 Dermatofibrosarcoma Protuberans and Dermatofibroma. Am J Dermatopathol.
- 344 2014;36(5):392-396. doi:10.1097/DAD.0b013e3182a15f3e
- 38. Kim JE, Lee JH, Jeong KH, Kim GM, Kang H. Notch Intracellular Domain Expression in Various
- 346 Skin Fibroproliferative Diseases. *Ann Dermatol.* 2014;26(3):332.
- 347 doi:10.5021/ad.2014.26.3.332
- 39. Kouki N, Ben Rejeb S, Cherif I, et al. Comparative expression profile of CD10 and cyclin D1 in
- cutaneous histiocytofibroma and dermatofibrosarcoma. *J Immunoassay Immunochem*.
- 350 2021;42(4):347-358. doi:10.1080/15321819.2020.1868000
- 40. Kreicher KL, Honda KS, Kurlander DE, Bordeaux JS. Hormone receptor expression in patients
- with dermatofibrosarcoma protuberans. *J Am Acad Dermatol*. 2016;75(6):1205-1209.
- 353 doi:10.1016/j.jaad.2016.07.011
- 41. Li FZ, Ye Q, Ran LW, Fang S. Adipophilin expression in skin lesions with clear cell histology. J
- 355 *Clin Pathol.* 2022;75(9):627-631. doi:10.1136/jclinpath-2021-207443

42. Liu F, Wang H, Wu G, Li C. Clinical and pathological studies of eight cases of lipidized fibrous histiocytoma. *Exp Ther Med*. 2023;25(2):93. doi:10.3892/etm.2023.11792

- 43. Lo C hai, Tsang P man, Cheng S ying, Ling C nam, Ho C lam. Myoid differentiation in dermatofibrosarcoma protuberans and its fibrosarcomatous variant: 10 years experience in a tertiary hospital. *Autopsy Case Rep.* 2022;12:e2021368. doi:10.4322/acr.2021.368
- 44. Meng T, Shi X, Wu S, Luo Y, Wang X, Long X. Hormone receptors analysis in Chinese patients
 with dermatofibrosarcoma protuberans. *J Surg Oncol*. 2018;118(1):157-166.
- 363 doi:10.1002/jso.25117
- 45. Moayed-Alaei L, Vargas AC, Adybeik D, Maclean F, Moir D. Analyzing the morphological
 spectrum of epithelioid fibrous histiocytoma and the immunohistochemical performance of
 the ALK D5F3 and ALK1 clones. *Hum Pathol*. 2022;120:46-56.
- 367 doi:10.1016/j.humpath.2021.12.004
- 46. Nakamura I, Kariya Y, Okada E, et al. A Novel Chromosomal Translocation Associated With
 COL1A2 PDGFB Gene Fusion in Dermatofibrosarcoma Protuberans: PDGF Expression as a
 New Diagnostic Tool. JAMA Dermatol. 2015;151(12):1330.
- 371 doi:10.1001/jamadermatol.2015.2389
- 47. Nam KH, Park SW, Yun SK. A clinicohistopathological analysis of cutaneous fibrous
 histiocytomas of the finger. *Indian J Dermatol*. 2020;65(5):401. doi:10.4103/ijd.IJD_366_18
- 48. Pan H, Byers J, Yin H, et al. The utility of TLE1 and BCOR as immunohistochemical.
- 49. Park S, Cho S, Kim M, et al. Dermatofibrosarcoma protuberans: A retrospective study of
 clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1
 expression. *J Am Acad Dermatol*. 2018;79(5):843-852. doi:10.1016/j.jaad.2018.05.016
- 50. Piombino E, Broggi G, Barbareschi M, et al. Wilms' Tumor 1 (WT1): A Novel Immunomarker
 of Dermatofibrosarcoma Protuberans—An Immunohistochemical Study on a Series of 114
 Cases of Bland-Looking Mesenchymal Spindle Cell Lesions of the Dermis/Subcutaneous
- Tissues. *Cancers*. 2021;13(2):252. doi:10.3390/cancers13020252
- 51. Pukhalskaya T, Smoller BR. TLE1 expression fails to distinguish between synovial sarcoma, atypical fibroxanthoma, and dermatofibrosarcoma protuberans. *J Cutan Pathol*.
- 384 2020;47(2):135-138. doi:10.1111/cup.13596
- 385 52. Russell-Goldman E, Dong F, Laga A, Hanna J. A Novel Fusion Partner, SP100, Drives Nuclear Dot Localization of ALK in Epithelioid Fibrous Histiocytoma. *Am J Dermatopathol*.
- 387 2023;45(8):539-543. doi:10.1097/DAD.000000000002475
- 53. Sadullahoglu C, Dere Y, Atasever TR, Oztop MT, Karaaslan O. The role of cd34 and d2-40 in the differentiation of dermatofibroma and dermatofibrosarcoma protuberans. *Turk J*
- 390 *Pathol.* Published online 2017. doi:10.5146/tjpath.2017.01402

391 54. Saeed O, Zhang S, Cheng L, Lin J, Alruwaii F, Chen S. STAT6 Expression in Solitary Fibrous

392 Tumor and Histologic Mimics: a Single Institution Experience. Appl Immunohistochem Mol

- 393 *Morphol.* 2020;28(4):311-315. doi:10.1097/PAI.000000000000745
- 394 55. Sandell RF, Carter JM, Folpe AL. Solitary (juvenile) xanthogranuloma: a comprehensive
- immunohistochemical study emphasizing recently developed markers of histiocytic lineage.
- 396 *Hum Pathol.* 2015;46(9):1390-1397. doi:10.1016/j.humpath.2015.05.025
- 397 56. Schechter SA, Bresler SC, Patel RM. Fat necrosis with an associated lymphocytic infiltrate
- 398 represents a histopathologic clue that distinguishes cellular dermatofibroma from
- dermatofibrosarcoma protuberans. *J Cutan Pathol*. 2020;47(10):913-916.
- 400 doi:10.1111/cup.13744
- 401 57. Serra-Guillén C, Llombart B, Nagore E, et al. High immunohistochemical nestin expression is
- associated with greater depth of infiltration in dermatofibrosarcoma protuberans: a study
- 403 of 71 cases. J Cutan Pathol. 2013;40(10):871-878. doi:10.1111/cup.12203
- 58. Shah KK, McHugh JB, Folpe AL, Patel RM. Dermatofibrosarcoma Protuberans of Distal
- 405 Extremities and Acral Sites: A Clinicopathologic Analysis of 27 Cases. *Am J Surg Pathol*.
- 406 2018;42(3):413-419. doi:10.1097/PAS.0000000000000998
- 407 59. Smith EH, Lowe L, Harms PW, Fullen DR, Chan MP. Immunohistochemical evaluation of P16
- 408 expression in cutaneous histiocytic, fibrohistiocytic and undifferentiated lesions. *J Cutan*
- 409 *Pathol.* 2016;43(8):671-678. doi:10.1111/cup.12730
- 410 60. Song JS, Kim EJ, Park CS, Cho KJ. Dermatofibrosarcoma Protuberans: An Immunomarker
- 411 Study of 57 Cases That Included Putative Mesenchymal Stem Cell Markers. *Appl*
- 412 *Immunohistochem Mol Morphol.* 2017;25(8):586-591. doi:10.1097/PAI.000000000000348
- 413 61. Thangaiah JJ, Westling BE, Roden AC, et al. Loss of dimethylated H3K27 (H3K27me2)
- 414 expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST):
- 415 An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic
- 416 tumors. Ann Diagn Pathol. 2022;59:151967. doi:10.1016/j.anndiagpath.2022.151967
- 417 62. Üyetürk Ü. Dermatofibrosarcoma Protuberans: A Rare Malignancy. *Turk J Oncol*. Published
- 418 online 2017. doi:10.5505/tjo.2017.1635
- 419 63. Vivero M, Doyle LA, Fletcher CDM, Mertens F, Hornick JL. GRIA 2 is a novel diagnostic
- 420 marker for solitary fibrous tumour identified through gene expression profiling.
- 421 *Histopathology*. 2014;65(1):71-80. doi:10.1111/his.12377
- 422 64. West KL, Cardona DM, Su Z, Puri PK. Immunohistochemical Markers in Fibrohistiocytic
- 423 Lesions: Factor XIIIa, CD34, S-100 and p75. Am J Dermatopathol. 2014;36(5).

- 424 65. Xiong JX, Cai T, Hu L, et al. Risk factors related to postoperative recurrence of dermatofibrosarcoma protuberans: A retrospective study and literature review. *World J Clin*
- 426 *Cases.* 2021;9(20):5442-5452. doi:10.12998/wjcc.v9.i20.5442
- 427 66. Xu S, Zhao L, Wang J. Atrophic dermatofibrosarcoma protuberans: a clinicopathological study of 16 cases. *Pathology (Phila)*. 2019;51(6):615-620. doi:10.1016/j.pathol.2019.06.002
- 429 67. Yamada Y, Ichiki T, Susuki Y, et al. Diagnostic utility of ERG immunostaining in 430 dermatofibroma. *J Clin Pathol*. 2023;76(8):536-540. doi:10.1136/jclinpath-2022-208158
- 431 68. Zhang X, Sun D, Zheng H, et al. Comprehensive analysis of transcriptome characteristics and identification of TLK2 as a potential biomarker in dermatofibrosarcoma protuberans. *Front Genet*. 2022;13:926282. doi:10.3389/fgene.2022.926282
- 434 69. Zhang Z, Lu Y, Shi C, Chen M, He X, Zhang H. Pediatric dermatofibrosarcoma protuberans: A
 435 clinicopathologic and genetic analysis of 66 cases in the largest institution in Southwest
 436 China. Front Oncol. 2023;13:1017154. doi:10.3389/fonc.2023.1017154
- 70. Zhou L, Xu H, Zhou J, et al. Nuclear TFE3 expression is a diagnostic marker for Desmoid-type fibromatosis. *Diagn Pathol.* 2019;14(1):34. doi:10.1186/s13000-019-0814-4
- 439 71. Haycox CL, Odland PB, Olbricht SM, Piepkorn M. dermatofibrosarcoma protuberans with 440 practical applications for diagnosis and treatment.

TABLES

441

442443444

445

Table 1. Immunohistochemical biomarkers applied in DF and their primary indication as evaluated in the studies reviewed.

Indication	Markers	Utility/Findings	
Diagnostic	CD34, FXIIIa, S100, SMA, Desmin, Vimentin	Classical diagnostic markers	
_	FOSB	Distinguish from pseudomyogenic	
		hemagioendothelioma ³¹	
	SOX9	Distinguish from AFH ¹⁶	
	TLE1, BCOR	Distinguish from AFH ⁴⁸	
	STAT6	Distinguish from SFT ²⁰	
	MITF, NKI/C3	Compare to expression in cellular	
		neurothekoma ⁹	
	TFE3	Compare expression to desmoid type	
		fibromatosis ⁷⁰ and evaluate histopathologic	
		features ^{36,45}	
	ERG ^{29,67} , WT1 ⁵⁰ , p75 ⁶⁴ , D2-40 ^{14,53}	Distinguish from DFSP and its mimics	
	CD10 ^{39,60} , CCND1 ³⁹ , LSP1 ³⁴ , CD68 ^{34,42,45,47}	Distinguish from DFSP	
	CD99	Distinguish from DFSP and describe	
		expression ^{37,60}	
Descriptive	MUC4	Describe features of lipidized fibrous	
		histiocytoma ⁴²	
	FGFR1-4, FGF2	Understand expression patterns and role in	
		pathogenesis ³²	

	ALL TOD GTATA EDIA GOVEDA	TT 1 . 1 . 1	
	Akt, mTOR, STAT3, ERK, CCND1	Understand expression pattern and assess role in recurrence ⁴⁹ ne, Characterize the immunophenotype of solitary	
	CD163 ^{45,55} , CD11c,CD31,CD45, lysozyme,		
	and CD4 ⁵⁵	xanthogranuloma in comparison to its	
		differential diagnoses (including BFH)	
	NCID ³⁸ , PRAME ¹⁸ Describe expression in va		
		fibroproliferative diseases	
	TGFb, TGFRb-1/2, SMAD3, VDR	Describe expression in DF, cutaneous	
		leiomyomas, and uterine leiomyomas ¹⁹	
	PanCK ^{42,45} , SOX10, p63, and EMA ⁴⁵ , P16 ^{59,69} ,	Describe expression	
	P53 ^{33,41} , CD105, CD133, Oct3/4, CD117, and		
	ALK ⁶⁰ , PDGFR α/β , PDGF $\alpha/\beta^{46,60}$, Nestin ⁴⁶		
Prognostic	Ki-67, MMP9	Association with high recurrence rate ¹¹	

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464 465

466

Abbreviations: AFH, angiomatoid fibrous histiocytoma; Akt, protein kinase B; ALK, anaplastic lymphoma kinase; BCOR, BCL6 corepressor; BHF, benign fibrous histiocytoma; CCND1, cyclin D1; CD, cluster of differentiation (CD34, CD10, CD68, CD99, CD163, CD11c, CD31, CD45, CD4, CD105, CD133, CD117); D2-40, podoplanin; DF, dermatofibroma; DFSP, dermatofibrosarcoma protuberans; EMA, Epithelial membrane antigen; ERG, erythroblast transformation specific related gene; ERK, extracellular signal-regulated kinase; FXIIIa, factor XIIIa; FGF2, fibroblast growth factor 2; FGFR1-4, fibroblast growth factor receptors 1-4; FOSB, FBJ murine osteosarcoma viral oncogene homolog B; Ki-67, Antigen Kiel 67; LSP1, lymphocyte-specific protein 1; MITF, microphthalmia-associated transcription factor; MMP, matrix metalloproteinase; mTOR, mammalian target of rapamycin; MUC4, mucin 4; NICD, notch intracellular domain; NKI/C3, also known as cluster of differentiation 68 (CD68); Oct3/4, octamer-binding transcription factor 3/4; P, protein (p75, p63, p16, p53); PanCK, pan-cytokeratin; PDGF α/β , platelet derived growth factor alpha and beta; PDGFR α/β , platelet derived growth factor receptor alpha and beta; PRAME, Preferentially expressed Antigen in Melanoma; SFT, solitary fibrous tumor; SMA, smooth muscle actin; SMAD3, suppressor of mothers against decapentaplegic homolog 3; SOX, SRY-related HMG box gene (SOX9, SOX10); STAT3, signal transducer and activator of transcription 3; STAT6, signal transducer and activator of transcription 6; TFE3, transcription factor binding to IGHM enhancer 3; TGFb, transforming growth factor beta; TGFRb-1/2, transforming growth factor beta receptor 1 and 2; TLE1, transducin-like enhancer of split 1; VDR, vitamin D receptor; WT1, Wilms tumor gene 1

Table 2. Immunohistochemical markers applied in DFSP and their primary indication as evaluated in the studies reviewed.

Indication	Markers	Utility/Findings	
Diagnostic	CD34, FXIIIa, SMA, S100, Desmin,	Classical diagnostic markers	
	Vimentin		
	GRIA2 ⁶³ , STAT6 ^{20,54,66}	Distinguish from SFT ²⁰ and describe expression	
	H3K27me3, H3K27me2	Distinguish PNST from its mimics ^{21,61}	
	_TLE1	Distinguish AFX and synovial sarcoma ⁵¹	
	EVG	Compare to expression in sclerotic fibroma and	
		perineuroma ⁸	
	ERG	Distinguish from its mimics ^{29,67}	
	WT1	Distinguish from DFSP and its mimics ⁵⁰	
	LSP1 ³⁴ , CD68 ^{37,66} , p75 ⁶⁴ , D2-40 ^{53,60} ,	Distinguish from DF	
	CD10 ^{39,41,60} , CCND1 ^{39,49}		
Descriptive	Melan-A ^{37,66} , PanCK and HMB45 ⁶⁶	Study features of atrophic DFSP	
	ER, PR	Describe role in pathogenesis/tumor growth ^{40,44}	
	FGFR1-4, FGF2	Understand expression patterns and role in	
		pathogenesis ³²	
	Akt ^{30,49} , mTOR, STAT3, and ERK ⁴⁹ , p-	Understand expression patterns and role in	
	4EBP1, p-S6RP, p-and mTOR ³⁰	pathogenesis	
	NTRK ¹⁷	Describe expression in soft tissue sarcomas	
	P16 ^{59,69}	Describe expression patterns	

	BCL-2 ^{23,65,69} , CD99 ^{23,37,60,69} , p63,	Describe expression patterns/understand	
	Myogenin ⁶⁹ , MSA ²³	clinicopathologic features	
	EMA	Describe expression ^{8,28,69} and assess relevance	
		to fibrosarcomatous transformation ⁴¹	
	CD105, CD133, ALK, Oct3/4, and	Describe expression	
	CD117 ⁶⁰ , PDGFR $\alpha/\beta^{23,30,60}$, PDGF $\alpha/\beta^{23,60}$,		
	FAM118B and TLK2 ⁶⁸ , PRAME ¹⁸		
Prognostic	Ki-67	Independent predictor of RFS ¹⁰	
	EZH2, EGFR, PD-L1, VEGF	Investigation as therapeutic targets ²³	
	Nestin ^{46,57}	Association of expression with degree of	
		invasion ⁵⁷	

468

469

470

471

472

473

474

475

476

477 478

479

480

481

482

483

484

485

486

487 488 489

490

491

492

Abbreviations: AFX, atypical fibroxanthoma; Akt, protein kinase B; ALK, anaplastic lymphoma kinase; BCL-2, bcell leukemia/lymphoma 2 protein; CCND1, cyclin D1; CD, cluster of differentiation (CD34, CD68, CD10, CD99, CD105, CD133, CD177); D2-40, podoplanin; DF, dermatofibroma; DFSP, dermatofibrosarcoma protuberans; EGFR, epidermal growth factor receptor; EMA, epithelial membrane antigen; ER, estrogen receptor; ERG, erythroblast transformation specific related gene; ERK, extracellular signal-regulated kinase; EVG, elastin Van Gieson; EZH2, enhancer of zeste homolog 2;FAM118B, family with sequence similarity 118 member B;FGF2, fibroblast growth factor 2; FGFR1-4, fibroblast growth factor receptors 1-4; FXIIIa, factor XIIIa; GRIA2, glutamate ionotropic receptor AMPA type subunit 2; H3K27me2, epigenetic modification to the DNA packaging protein Histone H2; H3K27me3, epigenetic modification to the DNA packaging protein Histone H3; HMB45, human melanoma black 45; Ki-67, Antigen Kiel 67; LSP1, lymphocyte-specific protein 1; Melan-A, melanoma antigen recognized by T cells; MSA, muscle specific actin; mTOR, mammalian target of rapamycin; NTRK, neurotrophic tyrosine receptor kinase; Oct3/4, octamer-binding transcription factor 3/4;P, protein; (p75, p16, p63); p-4EBP1, eukaryotic translation initiation factor 4E-binding protein 1; p-mTOR, phosphorylated mammalian target of rapamycin; p-S6RP, S6 ribosomal protein; PanCK, pan-cytokeratin; PDGFα/β, platelet derived growth factor alpha and beta; PDGFRα/β, platelet derived growth factor receptor alpha and beta; PD-L1, programmed death-ligand 1; PNST, peripheral nerve sheath tumor; PR, progesterone receptor; PRAME, Preferentially expressed Antigen in Melanoma; RFS, recurrence-free survival; SFT, solitary fibrous tumor; SMA, smooth muscle actin; STAT, signal transducer and activator of transcriptionSTAT6, signal transducer and activator of transcription 6;TLE1, transducinlike enhancer of split 1; TLK2, tousled-like kinase 2; VEGF, vascular endothelial growth factor; WT1, Wilms tumor gene 1.

Table 3. General trends of immunohistochemical expression for classical/well described markers for distinguishing DF and DFSP.

Listed		DF	DFSP	
markers	General	In evaluated studies	General	In evaluated studies
	expression (+/-)	n/total, (%)	expression (+/-)	n/total, (%)
CD34	-	35/226 (15.5)	+	980/1023 (95.8)
FXIIIa	+	163/189 (86.2)	-	28/108 (25.9)
SMA	+	63/183 (34.4)	-	26/370 (7)
S100	-	15/114 (13.1)	-	12/432 (2.8)
ALK	+	71/154 (46.1)	-	0/57 (0)
CD99	+	30/36 (83.3)	-	56/176 (31.8)
CD68	+	25/59 (42.4)	-	5/27 (18.5)
Desmin	-	0/41(0)	-	0/332 (0)
Vimentin	N/A	N/A	+	123/126 (97.6)

n/total where n=number of positive samples. Abbreviations: (+), positive for expression; (-), negative for expression; ALK, anaplastic lymphoma kinase; CD, cluster of differentiation

(CD34, CD99, CD68); DF, dermatofibroma; DFSP, dermatofibrosarcoma protuberans; FXIIIa, factor XIIIa; N/A, not available; SMA, smooth muscle actin.

Table 4. General trends of immunohistochemical expression for novel/emerging markers evaluated in distinguishing DF and DFSP.

Marker	Evidence (n positive/total)	Study
WT1	Negative in DF (0/15), positive in DFSP (54/57)	Piombino et al. (2021) ⁵⁰
Cx43	Positive in DF (16/16), Negative in DFSP (0/13 positive)	Fernandez-flores et al. (2023) ²⁶
LSP-1	Positive in DF (18/20), negative in DFSP (2/20)	Jin et al. (2015) ³⁴
ERG	87/97 DF positive with variable (50-89% cells) positive, 0/64 DFSP positive 15/15 DF positive, 6/9 DFSP positive	Yamada et al. (2023) ⁶⁷ Hengy et al. (2022) ²⁹
	<u> </u>	
РНН3	DF mean mitotic count 1.8 mm ² , DFSP mean mitotic count 0.5/mm ²	Agarwal et al. $(2017)^{12}$
Ki-67	Mean proliferative index in DF: 39.2mm ² , DFSP: 12.6 mm ²	Agarwal et al. (2017) ¹²
P75	0/30 DF positive, 17/32 DFSP positive	West et al. (2014) ⁶⁴
	Positive in DF (49/70)	Aslam et al. (2021) ¹⁴
D2-40	Positive in DF (23/30) and negative in DFSP (2/15 positive)	Sadullahoglu 2017 ⁵³
	DF 4/12 positive, DFSP 2/57 positive	Song et al. (2017) ⁶⁰
Oct3/4	0/12 DF, 0/57 DFSP	Song et al. (2017) ⁶⁰
CD10	12/12 DF, 23/57 DFSP	Song et al. (2017) ⁶⁰
	13/15 DF, 15/15 DFSP	Kouki et al. (2021) ³⁹
	12/15 DF, 15/15 DFSP	Kouki et al. (2021) ³⁰
FGF2 and FGFR4	Positive in DF (20/20), variable expressivity in DFSP (4/6 positive)	Ishigami et al. (2013) ³²
FGFR1-3	All cases negative in both DF (0/20) and DFSP (0/6)	Ishigami et al. (2013) ³²
P16	Positive in both DF (18/19) and DFSP (4/5)	Smith et al. (2016) ⁵⁹

Abbreviations: CD, cluster of differentiation (CD10); Cx43, connexin 43; D2-40, podoplanin; DF, dermatofibroma; DFSP, dermatofibrosarcoma protuberans; ERG, erythroblast transformation specific related gene; FGF2, fibroblast growth factor 2; FGFR1-3, fibroblast growth factor receptors 1-3; FGFR4, fibroblast growth factor receptor 4; Ki-67, Antigen Kiel 67; LSP1, lymphocyte-specific protein 1; Oct3/4, octamer-binding transcription factor 3/4; P, protein (p75, p16); PHH3, phosphohistone H3; WT1, Wilms tumor gene 1.

Figure 1. PRISMA flow diagram indicating the article selection process.

Figure 2. Frequency of IHC biomarker use across all studies (n=63). Bar plot indicating the frequency of IHC biomarkers assessed across all studies. Bars indicate the number of studies which evaluated a given marker.

SUPPLEMENTAL MATERIAL

Table S1. Study characteristics data extracted from the included studies (n=63).

Table S2. IHC expression data extracted from the included studies (n=63).

Figure S1. Frequency of IHC biomarker use in studies distinguishing between DF and DFSP (n=15). Bar plot indicating the frequency of IHC biomarkers assessed across studies which aimed to differentiate DF and DFSP. Bars indicate the number of studies which evaluated a given marker.

Figure 1.





Figure 2.

MARKERS ASSESSED IN ALL STUDIES (n=63)



Cx43,EGFR,ERK,EVG,EZH2,FAM118B,FGFR1,FGFR2,FGFR3, FGFR4,FOSB,GRIA2,H3K27me2,HMB45,LSP1,Lysozyme,MITF, MMP9, MSA, mTOR, MUC4, NCID, NKIC3, NTRK, Oct3/4, p4EBP1, P53,P75,pAkt,PDGFB,PDGFRb,PDL1,PHH3,pmTOR,pPDGFRa, pPDGFRb,PRAME,pS6RP,S100A6,SMAD3,SOX10,SOX9,STAT3, TLK2,VEGF,WT1,TGFb,PDGFRa,Fibronectin,TGFRb-1, TGFRb-2,VDR,Myogenin,FGF2